Introduction:Mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (pcALCL) are common subtypes of CTCLs. ALCANZA trial showed brentuximab vedotin (BV) significantly improved ORR4 (objective response rate lasting ≥ 4 months) in CD30+ CTCLs patients compared with conventional therapies (56.3% vs 12.5%, p<0.001).Methods:Adult patients with histologically confirmed CD30+ MF or pcALCL, who had received prior systemic treatment were eligible. BV 1.8 mg/kg was administered on day 1 of every 21days for up to 16 cycles.The primary endpoint was ORR4, which was defined by global response score (GRS), on the basis of skin evaluation (mSWAT), lymph node and visceral assessments, and circulating Sézary cells detection for MF patients.Objectives:This study C25029 (NCT05442554) evaluated the efficacy and safety of BV in Chinese CD30+ CTCL patients. Results: A total of 9 MF and 1 pcALCL patients (5 males and 5 females) with median age of 53 (range 43-83) years old were enrolled. ORR4 was reported as 60% (95%CI: 26.2, 87.8). Objective response was observed from 2 to 11 months after BV treatment for 7 responders (Fig1a). The skin lesions of all 10 patients improved with treatment (Fig1b). No progression or death event was observed. Grade 3 or higher TEAE was reported for 8 patients (80%). Three patients experienced drug related SAEs (dysuria, peripheral neuropathy, peripheral oedema, and decreased WBC count). PN events (PN of grade 2 and 3 and muscular weakness of grade 2) resulted in study drug discontinuation for 3 patients.Conclusions: BV showed durable antitumor activity with tolerable toxicity in adult Chinese patients with CD30+ CTCL.
